Quarterly Report · 10-Q
Enanta Pharmaceuticals, Inc.
ENTANASDAQEQUITYCurrent
Quarterly Report
Company context
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline
Current securities
As-filed source
As filedOpen full document ↗